Animal models of inhibitors.
Antibody responses to clotting factor concentrates remain a major treatment limitation. In conjucation with ongoing clinical studies, the pathogenesis and potential treatment of clotting factor immune responses is being evaluated in a variety of animal models.
Reipert
B
B
Baxter Bioscience, Vienna, Austria.
Arruda
V
V
Lillicrap
D
D
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D019774:Blood Coagulation Factor Inhibitors / Q000276:immunology*; D004195:Disease Models, Animal; D005164:Factor IX / Q000276:immunology* / Q000627:therapeutic use; D005169:Factor VIII / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000627:therapeutic use; D015316:Genetic Therapy; D006684:HLA-DR Antigens / Q000378:metabolism; D059811:HLA-DRB1 Chains; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D007108:Immune Tolerance / Q000276:immunology*; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology
D019774:Blood Coagulation Factor Inhibitors; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C489631:HLA-DRB1*15:01 antigen; D005169:Factor VIII; D005164:Factor IX